| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5697013 | Brachytherapy | 2017 | 8 Pages |
Abstract
In patients treated with IGABT, point A dose is not predictive of local control but a surrogate of the irradiated volume. Its relationships with the D90 CTVHR are indirect and complex rising the question of relevance of its reporting in routine.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Renaud Mazeron, Sebastien Gouy, Alexandre Escande, Isabelle Dumas, Eleonor Rivin del Campo, Enrica Bentivegna, Warren Bacorro, Dimitri Lefkopoulos, Eric Deutsch, Philippe Morice, Christine Haie-Meder, Cyrus Chargari,